The FDA has completed its 30-day review of an application for Hepzato in combination with standard of care in liver-dominant ...

Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic ...

SIRT with 90Y resin microspheres led to durable disease control in patients with gastrointestinal stromal tumor liver ...

Cancer spreads fast and hits hard, especially when it reaches other organs. Once that happens, treatments become less ...

Delcath Systems, Inc. announced that it has received clearance from the FDA to initiate patient enrollment of a phase 2 clinical ...

Katie Thurston shares about her stage 4 breast cancer journey Read ahead to find out how she finds hope reshapes goals and ...

Replimune Group, Inc.'s RP1 + OPDIVO for advanced melanoma gains FDA Priority Review. PDUFA date: July 22, 2025. Read more on ...

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer Delcath Systems, Inc. (NASDAQ: DCTH), an ...

It can take years for prostate cancer to turn castration-resistant, when cancer cells stop responding to hormonal therapy.

A humanized antibody undermines the metabolic checkpoint mediated by CD36 to restore anti-tumor immunity in mouse models of ...

Hepatocellular carcinoma (HCC) is a common malignant tumor and the third leading cause of cancer-related mortality. The lack ...